Insmed Incorporated (NASDAQ:INSM) Shares Sold by Cutter Capital Management LP

Cutter Capital Management LP lessened its holdings in Insmed Incorporated (NASDAQ:INSM) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 210,884 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the period. Insmed accounts for approximately 6.0% of Cutter Capital Management LP’s holdings, making the stock its 8th largest holding. Cutter Capital Management LP’s holdings in Insmed were worth $14,559,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its position in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in Insmed in the fourth quarter valued at approximately $47,000. Smartleaf Asset Management LLC raised its holdings in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in Insmed during the 4th quarter worth about $86,000.

Insider Buying and Selling

In other Insmed news, COO Roger Adsett sold 45,605 shares of the firm’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $3,689,444.50. Following the completion of the transaction, the chief operating officer now directly owns 189,157 shares in the company, valued at approximately $15,302,801.30. This trade represents a 19.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 79,350 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $6,419,415.00. Following the completion of the sale, the chief executive officer now directly owns 453,894 shares in the company, valued at $36,720,024.60. This trade represents a 14.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 368,737 shares of company stock valued at $29,364,317. 3.00% of the stock is owned by insiders.

Insmed Stock Up 0.4 %

INSM opened at $72.58 on Tuesday. The business has a 50 day simple moving average of $73.31 and a 200-day simple moving average of $73.44. The stock has a market capitalization of $13.20 billion, a P/E ratio of -12.98 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on INSM shares. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Morgan Stanley upped their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. UBS Group lifted their price target on Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. Finally, Stifel Nicolaus cut their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.